Open your mouth and forcefully spit the water out [Two-Stage / GS Designs]

posted by Helmut Homepage – Vienna, Austria, 2013-10-18 15:29 (4266 d 05:55 ago) – Posting: # 11695
Views: 26,277

Hi Shuanghe,

❝ Q: "..., we'd like to ask about the current status of 2-stage design BE study, ... if the BE protocol with Potvin's Method C is acceptable now ..."


❝ A: "Potvin's methods are not acceptable in EMA."


Simply mad. And I don’t mean the MAD.
Have you asked them which methods would be acceptable according to their impeccable wisdom instead? They should enlighten us simpletons.

❝ so, first question, how could it be? Have some of you guy's dossiers with Potvin's method(s) been approved/accepted (no deficient letter, rejection letter etc)?


Yes. For some recent (this year’s) experiences see slide 45 of this presentation. Method C [sic] accepted by Germany (RMS) and CMSs Austria, Denmark, Sweden, and The Netherlands. Spain asked for an all-fixed effects analysis (subjects within sequence were random in the original analysis).
Note that in a previous case (slide 44) MEB didn’t like intermediate power.

❝ I always had the impression that method B is practically mentioned in the guide. Not quite. :no: There's no mention of interim power analysis in the BE guide while method B... you know. So I guess the power analysis is probably the "evil" here causing all the fuss...


Maybe. I suspect the guys writing the GL failed to comprehend the published methods, which – with no exception! – depend on an intermediate power estimation step. I hope someone has the balls and goes for a referral. If a GL (not a law anyway) states 2×2=5 I would wholeheartedly ignore it for sure.

BTW, the additional term introduced in the Q&A Ref.7 is futile as well. I have heard that this section was excreted by EMA’s Biostatistical Working Party and the PK Working Party is just “hosting” it. What the heck? A paper “On the Statistical Model of the Two-Stage Design in Bioequivalence Assessment” by Karalis/Macheras is currently under review (J Pharm Pharmacol). From their key findings:

The overall performance in terms of % BE acceptance is identical. The additional term, ‘Sequence × Stage’, suggested in the EMA method is in most cases non-signi­fi­cant. The same results were obtained regardless of the type (fixed or random) of the effect applied to the ‘Subjects’ term.

And the conclusions:

Any BE study either finished or in progress which relies on the existing literature methodology leads to the same % BE acceptance as if it was analyzed with the recently proposed EMA method.

So what?

❝ There's rumour that some working party is currently discussing this topic. Anyone has any insight?


Not me.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,673 registered users;
43 visitors (0 registered, 43 guests [including 6 identified bots]).
Forum time: 21:24 CEST (Europe/Vienna)

Reach for the stars,
even if you have to stand on a cactus.    Susan Longacre

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5